Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)

Completed · Not applicable

Conditions studied: Diabetic Foot Ulcer

In brief

The primary objective of this study is to determine the outcomes of patients who receive a certain type of skin substitute called RestrataTM Wound Matrix (Restrata™). Results of this study may be used to make decisions on whether to conduct additional studies on this particular wound matrix product. RestrataTM has been cleared by the Food and Drug Administration for use in certain types of ulcer treatments, including the type that will be part of this study (diabetic foot ulcers).

Key facts

Study ID

NCT03312595

Run by

Acera Surgical, Inc.

People needed

30

Starts

2017-09-14

Expected to finish

2018-07-30

Last updated by the study team

2025-09-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female age 18 or older
• Patient's ulcer must be diabetic in origin, located at least in part on the plantar surface and larger than 1cm2 after the run-in period. Debridement will be done prior to randomization. Subject's informed consent for participating in this study, must be obtained prior to proceeding with sharp debridement
• Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA).
• Ulcer must be present for a minimum of four weeks before enrollment/randomization, with documented failure of prior treatment to heal the wound. A two-week run in period will precede enrollment/randomization in the trial to document the indolent nature of the patients selected
• Patient does not exhibit clinical signs / symptoms of infection upon gross observation (at least 3 of the following: pain, redness, purulence, exudate, temperature) or have been diagnosed with an active infection at time of screening
• Patient is willing to provide informed consent and is willing to participate in all procedures and follow up evaluations necessary to complete the study
• Patient has adequate control of diabetes, as demonstrated by one of the following within 30 days of screening:
• HbA1c < 12%
• Serum Creatinine < 3.0mg/dl
• Patient has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days of the first screening visit:
• Dorsum transcutaneous oxygen test (TcPO2) with results
• ≥30mmHg, OR
• ABIs with results of ≥0.7 and ≤1.5, OR
• Doppler arterial waveforms, which are triphasic or biphasic at the ankle of affected leg

You may not qualify if…

• Patients presenting with an ulcer probing to bone (UT Grade IIIA-D)
• Patients whose index diabetic foot ulcers are greater than 25cm2
• Patient has an additional wound within 3cm of the study wound
• Patients not in reasonable metabolic control
• Patients with a known history of poor compliance with medical treatments
• Patients who have been previously enrolled into this study, or are presently participating in a clinical trial with DFU indications
• Patients with known or suspected local skin malignancy to the index diabetic ulcer
• Patients diagnosed with autoimmune connective tissues diseases
• Patients that have received a graft material on the study ulcer within the previous 30 days
• Patients who are pregnant or breast feeding
• Patients who are taking medications that are considered immune system modulator
• Study wound has closed > 30% over the two-week run-in period
• Patients with a known allergy to resorbable suture materials

Where it is running

• Associated Foot & Ankle Specialists — Phoenix, Arizona, United States
• Arizona Reginal Medical Research — Tucson, Arizona, United States
• SAVAHCS — Tucson, Arizona, United States
• Advanced Foot Care And Clinical Research Center — Fresno, California, United States
• Richard C. Galperin, DPM — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.